Use: Labeled indications
- INDICATIONS AND USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
Full indications and usage US FDA label
INDICATIONS AND USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations.
Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.
NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available.
Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae.
Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established.
Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes. Abscesses should be surgically drained as clinically indicated.
NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See DOSAGE AND ADMINISTRATION.) Acute maxillary sinusitis caused by Haemophilusinfluenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis.
Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiellapneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus. NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents.
(See CLINICAL STUDIES section.) Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets, and other antibacterial drugs, cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Known allergy to cefpodoxime or other cephalosporins
Contraindications (US label) US FDA label
CONTRAINDICATIONS Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.
Dosing: Adult
- Pharyngitis or tonsillitis: 100 mg every 12 hours for 5 to 10 days
- Community-acquired pneumonia: 200 mg every 12 hours for 14 days
- Skin and skin structure: 400 mg every 12 hours for 7 to 14 days
- Uncomplicated urinary tract infection: 100 mg every 12 hours for 7 days
- Uncomplicated gonorrhea: 200 mg once
- Administration: Take tablets with food
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION (See INDICATIONS AND USAGE for indicated pathogens.) Film-coated Tablets Cefpodoxime Proxetil Tablets, USP should be administered orally with food to enhance absorption. (See CLINICAL PHARMACOLOGY.) The recommended dosages, durations of treatment, and applicable patient population are as described in the following chart: Adults and Adolescents (age 12 years and older) Type of Infection Total Daily Dose Dose Frequency Duration Pharyngitis and/or tonsillitis 200 mg 100 mg Q 12 hours 5 to 10 days Acute community acquired - pneumonia 400 mg 200 mg Q 12 hours 14 days Acute bacterial exacerbations of chronic bronchitis 400 mg 200 mg Q 12 hours 10 days Uncomplicated gonorrhea (men and women) and rectal gonococcal infections (women) 200 mg single dose Skin and skin structure 800 mg 400 mg Q 12 hours 7 to 14 days Acute maxillary sinusitis 400 mg 200 mg Q 12 hours 10 days Uncomplicated urinary tract infection 200 mg 100 mg Q 12 hours 7 days Patients with Renal Dysfunction For patients with severe renal impairment (<30 mL/min creatinine clearance), the dosing intervals should be increased to Q 24 hours.
In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis. When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to estimate creatinine clearance (mL/min). For this estimate to be valid, the serum creatinine level should represent a steady state of renal function.
Males: Weight (kg) × (140 - age) (mL/min) 72 × serum creatinine (mg/100 mL) Females: 0.85 × above value (mL/min) Patients with Cirrhosis Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) are similar to those in healthy subjects. Dose adjustment is not necessary in this population.
Dosing: Altered kidney function
About 29% to 33% of a cefpodoxime dose is excreted unchanged in urine, and its half-life rises from about 3.5 to 9.8 hours as kidney function falls. The US label lengthens the interval to every 24 hours when creatinine clearance (CrCl) is below 30 mL/min, and gives the dose three times a week after hemodialysis.
Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault); cut-off 30.
Show full dosing details
- CrCl ≥60 mL/min
- No dose change (label).
- CrCl 30–59 mL/min
- No dose change; the label changes the interval only below CrCl 30 (label).
- CrCl 15–29 mL/min
- CrCl below 30: usual dose every 24 hours (label).
- CrCl <15 mL/min (not on dialysis)
- CrCl below 30: usual dose every 24 hours (label).
- Hemodialysis (intermittent)
- Usual dose three times a week, after each hemodialysis (label). A 3-hour session removes about 23% of a dose.
- Peritoneal dialysis
- No peritoneal dialysis dosing in label. Specialist input.
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Partly: about 23% of a dose removed in a 3-hour hemodialysis (label). Protein binding 21% to 33%.
- Monitoring CrCl for dose; kidney function with nephrotoxic drugs (label); diarrhea (CDAD).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose (label).
- eGFR 30–59
- No pediatric kidney dosing in this tablet label. Specialist input.
- eGFR 15–29
- No pediatric kidney dosing in this tablet label. Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in this tablet label. Specialist input.
- Hemodialysis (intermittent)
- No pediatric kidney dosing in this tablet label. Specialist input.
- Peritoneal dialysis
- No pediatric kidney dosing in this tablet label. Specialist input.
- CRRT
- No pediatric kidney dosing in this tablet label. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Dosage and administration (renal excerpts) US FDA label
DOSAGE AND ADMINISTRATION (See INDICATIONS AND USAGE for indicated pathogens.) Film-coated Tablets Cefpodoxime Proxetil Tablets, USP should be administered orally with food to enhance absorption. ( See CLINICAL PHARMACOLOGY .) The recommended dosages, durations of treatment, and applicable patient population are as described in the following chart: Adults and Adolescents (age 12 years and older) Type of Infection Total Daily Dose Dose Frequency Duration Pharyngitis and/or tonsillitis 200 mg 100 mg Q 12 hours 5 to 10 days Acute community acquired - pneumonia 400 mg 200 mg Q 12 hours 14 days Acute bacterial exacerbations of chronic bronchitis 400 mg 200 mg Q 12 hours 10 days Uncomplicated gonorrhea (men and women) and rectal gonococcal infections (women) 200 mg single dose Skin and skin structure 800 mg 400 mg Q 12 hours 7 to 14 days Acute maxillary sinusitis 400 mg 200 mg Q 12 hours 10 days Uncomplicated urinary tract infection 200 mg 100 mg Q 12 hours 7 days Patients with Renal Dysfunction For patients with severe renal impairment (<30 mL/min creatinine clearance), the dosing intervals should be increased to Q 24 hours.
In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.
When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to estimate creatinine clearance (mL/min).
For this estimate to be valid, the serum creatinine level should represent a steady state of renal function.
Dosing: Pediatric
- Approved ages
- Tablets: adolescents 12 years and older (label).
- Usual dose
- 12 years and older: adult doses (label). Younger children use the suspension, which is not covered by this tablet label.
- Maximum dose
- 400 mg every 12 hours (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use Safety and efficacy in infants less than 2 months of age have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Of the 3338 patients in multiple-dose clinical studies of cefpodoxime proxetil film-coated tablets, 521 (16%) were 65 and over, while 214 (6%) were 75 and over. No overall differences in effectiveness or safety were observed between the elderly and younger patients. In healthy geriatric subjects with normal renal function, cefpodoxime half-life in plasma averaged 4.2 hours and urinary recovery averaged 21% after a 400 mg dose was given every 12 hours for 15 days.
Other pharmacokinetic parameters were unchanged relative to those observed in healthy younger subjects. Dose adjustment in elderly patients with normal renal function is not necessary.
Dosage forms
Philippines
- Film-coated tablet: 100 mg, 200 mg
- Granule for suspension: 50 mg/5 mL
- Powder for suspension: 50 mg/5 mL, 100 mg/5 mL
Registered products in the Philippines
36 products registered with the Food and Drug Administration (FDA) Philippines list Cefpodoxime as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products36
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CebarcCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu-Alu Blister Pack x 5's (Box of 10's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DRP-4341 | Jan 31, 2027 | |
CefdomedCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.India | Auspicia Inc.Importer: Pharmakon Biotec Inc. | DRP-13322-01 | Jan 26, 2028 | |
CefdotabCefpodoxime (as Proxetil) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DR-XY43280 | Mar 11, 2029 | |
CefdotabCefpodoxime (as Proxetil) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14611 | Mar 11, 2029 | |
CefdotabCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. LtdIndia | Jazmark PharmaceuticalImporter: Ambica International Corporation | DRP-5225 | Mar 25, 2029 | |
Ceffdo-200Cefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Brawn Laboratories LimitedIndia | Jazmark PharmaceuticalImporter: Ambica International Corporation | DRP-6164-02 | May 22, 2030 | |
CefodexisCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13322-05 | Jan 26, 2028 | |
CefonavCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: Pharmakon Biotec Inc. | DRP-13322-03 | Jan 26, 2028 | |
Ceforan-200Cefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu-Alu blister pack x 7's (Box of 14's) | Rx | Drug International LimitedBangladesh | JAZMARK PHARMACEUTICAL | DRP-5610 | Aug 14, 2028 | |
Cefpo-100Cefpodoxime (as Proxetil) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) | Rx | Oman Pharmaceutical Products Co., LLCOman | Atlantic Pharmaceuticals, Inc. | DR-XY47722 | Feb 10, 2027 | |
Cefpo-200Cefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) | Rx | Oman Pharmaceutical Products Co., LLCSultanate of Oman | Atlantic Pharmaceuticals, Inc. | DR-XY47681 | Jan 21, 2032 | |
CefpomedCefpodoxime (as proxetil) | 200mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt.Ltd.India | Teramedix Pharma Trading Inc. | DR-XY47313 | Dec 15, 2026 | |
CefporichCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Brawn Laboratories LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-6164-03 | May 22, 2030 | |
CifambicCefpodoxime (as proxetil) | 200 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Innova Captab Ltd. (Unit II)India | Ambica International Corporation | DRP-13939 | May 18, 2028 | |
DorexcefCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Brawn Laboratories LimitedIndia | Rexmed Pharmaceutical SalesImporter: Ambica International Corporation | DRP-6164-04 | May 22, 2030 | |
DoxieCefpodoxime (as proxetil) | 100 mg/5 mL Powder for Suspension60 mL HDPE Bottle x 1's | Rx | Scott-Edil Advance Research Laboratories & Education LimitedIndia | I.E Medica Inc.Trader: I Care Formulations | DRP-10068 | Dec 4, 2030 | |
DypodoximeCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Pharmakon Biotec Inc. | DRP-13322-02 | Jan 26, 2028 | |
Kefodox-100Cefpodoxime (as proxetil) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.Kerala India | Pharmastar Int'l Trading Corp. | DRP-6704 | May 24, 2031 | |
KefpoximeCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 10's,30's and 100's) | Rx | Scott- Edil Advance Research Laboratories & Education LimitedIndia | I.E MEDICA INC. | DRP-10069 | Oct 28, 2030 | |
NefidoximeCefpodoxime (as proxetil) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Brawn Laboratories Ltd.India | Ambica International Corporation | DRP-5162 | Feb 11, 2029 | |
NefidoximeCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Brawn Laboratories LimitedIndia | Pharma King DistributorImporter: Ambica International Corporation | DRP-6164 | May 22, 2030 | |
Oxef-200Cefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Euro-Health Care Exponents, Inc.Trader: Aldril Pharmaceuticals, Inc. | DRP-7109-04 | Sep 3, 2029 | |
PodoxiCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | SANCE LABORATORIES PVT. LTD.India | BIOCARE LIFESCIENCES, INC. | DRP-5165 | Feb 21, 2029 | |
PodoxiCefpodoxime (as proxetil) | 50 mg/5 mL Powder for SuspensionHDPE Bottle x 30mL Box of 1's | Rx | Sance Laboratories Pvt. Ltd.India | Biocare Lifesciences, Inc.Trader: Parabolic Drug Limited | DRP-4819 | Oct 14, 2028 | |
PodoxidanCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Brawn Laboratories LimitedIndia | D & G PharmaImporter: Ambica International Corporation | DRP-6164-05 | May 22, 2030 | |
S-FoximeCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 10's | Rx | Brawn Laboratories LimitedIndia | Starpharm, Inc.Importer: Ambica International Corporation | DRP-6164-01 | May 22, 2030 | |
StaneftCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.India | Ellebasy Medicale Group Inc.Importer: Pharmakon Biotec Inc. | DRP-13322-04 | Jan 26, 2028 | |
SwichCefpodoxime (as proxetil) | 100 mg/5 mL powder for suspension60 mL HDPE Bottle x 1's (Box of 1's) | Rx | Scott Edil Advance research Laboratories & education LimitedIndia | ALKEM LABORATORIES CORPORATIONImporter: I.E. Medica, Inc.Trader: I CARE FORMULATIONS | DRP-10068-02 | Sep 22, 2031 | |
SwichCefpodoxime (as proxetil) | 200mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Scott-Edil Advance Research Laboratories & Education LimitedIndia | ALKEM LABORATORIES CORPORATIONImporter: I.E. Medica, Inc.Trader: I Care Formulations | DRP-10069-02 | Oct 9, 2031 | |
TrizefCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Aldril Pharmaceuticals, Inc. | DRP-7109-03 | Sep 3, 2029 | |
TrizefCefpodoxime Proxetil | 50 mg / 5 mL Granules for SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-16521 | Dec 23, 2028 | |
TrizefCefpodoxime Proxetil | 50 mg/5 mL Granules for SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DR-XY35252 | Dec 23, 2028 | |
Xilpod-200Cefpodoxime ( As Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Sance Laboratories Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13322 | Jan 26, 2028 | |
ZefoCefpodoxime (as Proxetil) | 200 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | All-Bio Pharma, Inc. | DRP-5225-01 | Mar 25, 2029 | |
ZudemCefpodoxime (as proxetil) | 200 mg Film-Coated TabletAlu/Clear PVCD Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-7109 | Sep 3, 2029 | |
ZudemCefpodoxime (as proxetil) | 50 mg/5 mL Granules for SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-8167 | Jun 18, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.
IF AN ALLERGIC REACTION TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefpodoxime proxetil tablets, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. A concerted effort to monitor for C. difficile in cefpodoxime-treated patients with diarrhea was undertaken because of an increased incidence of diarrhea associated with C. difficile in early trials in normal subjects.
C. difficile organisms or toxin was reported in 10% of the cefpodoxime-treated adult patients with diarrhea; however, no specific diagnosis of pseudomembranous colitis was made in these patients. In post-marketing experience outside the United States, reports of pseudomembranous colitis associated with the use of cefpodoxime proxetil have been received.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Antacids, H2 blockers | Adjust or monitor | Absorption reduced by 27% to 32% (label). | Separate from antacids; avoid H2 blockers if possible. |
| Probenecid | Minor | AUC up about 31% (label). | Usually no action. |
| Nephrotoxic drugs | Adjust or monitor | Nephrotoxicity not seen alone, but monitor (label). | Monitor kidney function. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC).
Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. Nephrotoxic drugs Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.
Adverse reactions
Common
- Diarrhea (7%, dose-related), nausea (3.3%)
- Vaginal fungal or vulvovaginal infections
- Abdominal pain, headache
Serious
- Anaphylaxis (cross-reactivity with penicillins up to 10%)
- Clostridioides difficile-associated diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Clinical Trials Film-coated Tablets (Multiple dose) In clinical trials using multiple doses of cefpodoxime proxetil film-coated tablets, 4696 patients were treated with the recommended dosages of cefpodoxime (100 to 400 mg Q 12 hours). There were no deaths or permanent disabilities thought related to drug toxicity.
One-hundred twenty-nine (2.7%) patients discontinued medication due to adverse events thought possibly or probably related to drug toxicity. Ninety-three (52%) of the 178 patients who discontinued therapy (whether thought related to drug therapy or not) did so because of gastrointestinal disturbances, nausea, vomiting, or diarrhea.
The percentage of cefpodoxime proxetil-treated patients who discontinued study drug because of adverse events was significantly greater at a dose of 800 mg daily than at a dose of 400 mg daily or at a dose of 200 mg daily. Adverse events thought possibly or probably related to cefpodoxime in multiple-dose clinical trials (N=4696 cefpodoxime-treated patients) were: Incidence Greater Than 1 % Diarrhea 7 % Diarrhea or loose stools were dose-related: decreasing from 10.4% of patients receiving 800 mg per day to 5.7% for those receiving 200 mg per day.
Of patients with diarrhea, 10% had C. difficile organism or toxin in the stool.(See WARNINGS.) Nausea 3.3 % Vaginal Fungal Infections 1 % Vulvovaginal Infections 1.3 % Abdominal Pain 1.2 % Headache 1 % Incidence Less Than 1 %: By body system in decreasing order Clinical Studies Adverse events thought possibly or probably related to cefpodoxime proxetil that occurred in less than 1% of patients (N=4696) Body – fungal infections, abdominal distention, malaise, fatigue, asthenia, fever, chest pain, back pain, chills, generalized pain, abnormal microbiological tests, moniliasis, abscess, allergic reaction, facial edema, bacterial infections, parasitic infections, localized edema, localized pain. Cardiovascular – congestive heart failure, migraine, palpitations, vasodilation, hematoma, hypertension, hypotension.
Digestive – vomiting, dyspepsia, dry mouth, flatulence, decreased appetite, constipation, oral moniliasis, anorexia, eructation, gastritis, mouth ulcers, gastrointestinal disorders, rectal disorders, tongue disorders, tooth disorders, increased thirst, oral lesions, tenesmus, dry throat, toothache. Hemic and Lymphatic – anemia.
Metabolic and Nutritional – dehydration, gout, peripheral edema, weight increase. Musculo-skeletal – myalgia. Nervous – dizziness, insomnia, somnolence, anxiety, shakiness, nervousness, cerebral infarction, change in dreams, impaired concentration, confusion, nightmares, paresthesia, vertigo. Respiratory – asthma, cough, epistaxis, rhinitis, wheezing, bronchitis, dyspnea, pleural effusion, pneumonia, sinusitis.
Skin – urticaria, rash, pruritus non-application site, diaphoresis, maculopapular rash, fungal dermatitis, desquamation, dry skin non-application site, hair loss, vesiculobullous rash, sunburn. Special Senses – taste alterations, eye irritation, taste loss, tinnitus. Urogenital – hematuria, urinary tract infections, metrorrhagia, dysuria, urinary frequency, nocturia, penile infection, proteinuria, vaginal pain.
Film-coated Tablets (Single dose) In clinical trials using a single dose of cefpodoxime proxetil film-coated tablets, 509 patients were treated with the recommended dosage of cefpodoxime (200 mg). There were no deaths or permanent disabilities thought related to drug toxicity in these studies. Adverse events thought possibly or probably related to cefpodoxime in single-dose clinical trials conducted in the United States were: Incidence Greater Than 1% Nausea 1.4 % Diarrhea 1.2 % Incidence Less Than 1 % Central Nervous System: Dizziness, headache, syncope.
Dermatologic: Rash. Genital: Vaginitis. Gastrointestinal: Abdominal pain. Psychiatric: Anxiety. Laboratory Changes Significant laboratory changes that have been reported in adult and pediatric patients in clinical trials of cefpodoxime proxetil, without regard to drug relationship, were: Hepatic: Transient increases in AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.
Hematologic: Eosinophilia, leukocytosis, lymphocytosis, granulocytosis, basophilia, monocytosis, thrombocytosis, decreased hemoglobin, decreased hematocrit, leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, thrombocythemia, positive Coombs’ test, and prolonged PT, and PTT. Serum Chemistry: Hyperglycemia, hypoglycemia, hypoalbuminemia, hypoproteinemia, hyperkalemia, and hyponatremia.
Renal: Increases in BUN and creatinine. Most of these abnormalities were transient and not clinically significant. Post-marketing Experience The following serious adverse experiences have been reported: allergic reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and serum sickness-like reactions, pseudomembranous colitis, bloody diarrhea with abdominal pain, ulcerative colitis, rectorrhagia with hypotension, anaphylactic shock, acute liver injury, in utero exposure with miscarriage, purpuric nephritis, pulmonary infiltrate with eosinophilia, and eyelid dermatitis.
One death was attributed to pseudomembranous colitis and disseminated intravascular coagulation. Cephalosporin Class Labeling In addition to the adverse reactions listed above which have been observed in patients treated with cefpodoxime proxetil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: Adverse Reactions and Abnormal Laboratory Tests: Renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, serum sickness-like reaction, hemorrhage, agranulocytosis, and pancytopenia.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced.(See DOSAGE AND ADMINISTRATION and OVERDOSAGE.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Adverse reaction frequency tables (US label) US FDA label
| Diarrhea | 7 % |
| Nausea | 3.3 % |
| Vaginal Fungal Infections | 1 % |
| Vulvovaginal Infections | 1.3 % |
| Abdominal Pain | 1.2 % |
| Headache | 1 % |
| Nausea | 1.4 % |
| Diarrhea | 1.2 % |
Monitoring parameters
- CrCl for dose; kidney function with nephrotoxic drugs (label); diarrhea (CDAD). Kidney
- CrCl for dose
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects Pregnancy Category B Cefpodoxime proxetil was neither teratogenic nor embryocidal when administered to rats during organogenesis at doses up to 100 mg/kg/day (2 times the human dose based on mg/m2) or to rabbits at doses up to 30 mg/kg/day (1 to 2 times the human dose based on mg/m2). There are, however, no adequate and well-controlled studies of cefpodoxime proxetil use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Cefpodoxime is excreted in human milk. In a study of 3 lactating women, levels of cefpodoxime in human milk were 0%, 2% and 6% of concomitant serum levels at 4 hours following a 200 mg oral dose of cefpodoxime proxetil. At 6 hours post-dosing, levels were 0%, 9% and 16% of concomitant serum levels. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pharmacokinetics
Key PK parameters
| Half-life | About 3.3 hours (4.2 hours in older adults) |
|---|---|
| Half-life in kidney failure (ESKD) kidney | 5.9 hours at CrCl 30–49; 9.8 hours at CrCl 5–29 (label) |
| Protein binding | 21% to 33% |
| Metabolism (CYP, transporters) | Proxetil prodrug de-esterified to cefpodoxime |
| Active metabolites | Cefpodoxime (from the prodrug) |
| Renal excretion kidney | 29% to 33% unchanged in urine in 12 hours |
| Dialyzability kidney | Partly (about 23% per 3-hour session) |
CLINICAL PHARMACOLOGY Absorption and Excretion Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime.
Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours.
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
In subjects with moderate (30 to 49 mL/min creatinine clearance) or severe renal impairment (5 to 29 mL/min creatinine clearance), the half-life increased to 5.9 and 9.8 hours, respectively.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Absorption and Excretion Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically.
Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime in vivo. Effects of Food The extent of absorption (mean AUC) and the mean peak plasma concentration increased when film coated tablets were administered with food.
Following a 200 mg tablet dose taken with food, the AUC was 21 to 33% higher than under fasting conditions, and the peak plasma concentration averaged 3.1 mcg/mL in fed subjects versus 2.6 mcg/mL in fasted subjects. Time to peak concentration was not significantly different between fed and fasted subjects. When a 200 mg dose of the suspension was taken with food, the extent of absorption (mean AUC) and mean peak plasma concentration in fed subjects were not significantly different from fasted subjects, but the rate of absorption was slower with food (48% increase in T max).
Pharmacokinetics of cefpodoxime proxetil film-coated tablets Over the recommended dosing range (100 to 400 mg), the rate and extent of cefpodoxime absorption exhibited dose-dependency; dose-normalized C max and AUC decreased by up to 32% with increasing dose. Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
Mean C max was 1.4 mcg/mL for the 100 mg dose, 2.3 mcg/mL for the 200 mg dose, and 3.9 mcg/mL for the 400 mg dose. In patients with normal renal function, neither accumulation nor significant changes in other pharmacokinetic parameters were noted following multiple oral doses of up to 400 mg Q 12 hours. Cefpodoxime Plasma Levels (mcg/mL) in Fasted Adults After Film-coated Tablet Administration (Single Dose) Dose Time after Oral Ingestion (Cefpodoxime Equivalents) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
Skin Blister Following multiple-dose administration every 12 hours for 5 days of 200 mg or 400 mg cefpodoxime proxetil, the mean maximum cefpodoxime concentration in skin blister fluid averaged 1.6 and 2.8 mcg/mL, respectively. Skin blister fluid cefpodoxime levels at 12 hours after dosing averaged 0.2 and 0.4 mcg/mL for the 200 mg and 400 mg multiple-dose regimens, respectively.
Tonsil Tissue Following a single, oral 100 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in tonsil tissue averaged 0.24 mcg/g at 4 hours post-dosing and 0.09 mcg/g at 7 hours post-dosing. Equilibrium was achieved between plasma and tonsil tissue within 4 hours of dosing. No detection of cefpodoxime in tonsillar tissue was reported 12 hours after dosing.
These results demonstrated that concentrations of cefpodoxime exceeded the MIC 90 of S. pyogenes for at least 7 hours after dosing of 100 mg of cefpodoxime proxetil. Lung Tissue Following a single, oral 200 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in lung tissue averaged 0.63 mcg/g at 3 hours post-dosing, 0.52 mcg/g at 6 hours postdosing, and 0.19 mcg/g at 12 hours post-dosing.
The results of this study indicated that cefpodoxime penetrated into lung tissue and produced sustained drug concentrations for at least 12 hours after dosing at levels that exceeded the MIC 90 for S. pneumoniae and H. influenzae. CSF Adequate data on CSF levels of cefpodoxime are not available. Effects of Decreased Renal Function Elimination of cefpodoxime is reduced in patients with moderate to severe renal impairment (<50 mL/min creatinine clearance).
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION.) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours. In subjects with moderate (30 to 49 mL/min creatinine clearance) or severe renal impairment (5 to 29 mL/min creatinine clearance), the half-life increased to 5.9 and 9.8 hours, respectively.
Approximately 23% of the administered dose was cleared from the body during a standard 3-hour hemodialysis procedure. Effect of Hepatic Impairment (cirrhosis) Absorption was somewhat diminished and elimination unchanged in patients with cirrhosis. The mean cefpodoxime T 1/2 and renal clearance in cirrhotic patients were similar to those derived in studies of healthy subjects.
Ascites did not appear to affect values in cirrhotic subjects. No dosage adjustment is recommended in this patient population. Pharmacokinetics in Elderly Subjects Elderly subjects do not require dosage adjustments unless they have diminished renal function. (See PRECAUTIONS.) In healthy geriatric subjects, cefpodoxime half-life in plasma averaged 4.2 hours (vs 3.3 in younger subjects) and urinary recovery averaged 21% after a 400 mg dose was administered every 12 hours.
Other pharmacokinetic parameters (C max, AUC, and T max) were unchanged relative to those observed in healthy young subjects. Microbiology Mechanism of Action Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Mechanism of Resistance Resistance to cefpodoxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. Cefpodoxime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the Indications and Usage (1) section: Gram-positive bacteria Staphylococcus aureus (methicillin-susceptible strains, including those producing penicillinases) Staphylococcus saprophyticus Streptococcus pneumoniae (excluding penicillin-resistant isolates) Streptococcus pyogenes Gram-negative bacteria Escherichia coli Klebsiella pneumoniae Proteus mirabilis Haemophilus influenzae (including beta-lactamase producing isolates) Moraxella catarrhalis Neisseria gonorrhoeae (including penicillinase-producing isolates) The following in vitro data are available, but their clinical significance is unknown.
At least 90 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefpodoxime. However, the efficacy of cefpodoxime in treating clinical infections due to these microorganisms has not been established in adequate and well controlled clinical trials.
Gram-positive bacteria Streptococcus agalactiae Streptococcus spp. (Groups C, F, G) Gram-negative bacteria Citrobacterdiversus Klebsiellaoxytoca Proteus vulgaris Providenciarettgeri Haemophilusparainfluenzae Anaerobic Gram-positive bacteria Peptostreptococcusmagnus Susceptibility Test Methods For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cefpodoxime Proxetil · Ascend Laboratories, LLC [US FDA-approved label, version 3, October 22, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Ascend Laboratories, LLC. (2026). Cefpodoxime proxetil tablets, USP [Prescribing information; US FDA-approved label, ANDA210568, set ID ce5646cb-a450-4c2c-8499-6ecf71b12b0e, version effective October 22, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .